Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron,Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy |
| |
| Authors: | Satoshi Yokoyama Satoshi Tamaru Shinya Tamaki Daisuke Nakanishi Akiya Mori Tomokazu Yamakawa Takaaki Ao Yasuhiko Sakata Toshiro Mizuno Takuya Iwamoto Kenichi Watanabe Makoto Simomura Keiki Kawakami Naomi Konishi Shinichi Kageyama Shoichiro Ohtani Tomomi Yamada Susumu Ban Kazuya Ooi |
| |
| Affiliation: | 1. Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan;2. Clinical Research Support Center, Mie University Hospital Hematology and Oncology, Mie University Hospital, Tsu, Japan;3. Department of Pharmacy, Hokkaido Cancer Center, Sapporo, Japan;4. Department of Pharmacy, Matsusaka City Hospital, Matsusaka, Japan;5. Department of Pharmacy, Suzuka General Hospital, Suzuka, Japan;6. Department of Pharmacy, Mie Prefectural General Medical Center, Yokkaichi, Japan;7. Division of Pharmacy, Suzuka Kaisei Hospital, Suzuka, Japan;8. Department of Pharmacy, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan;9. Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan;10. Department of Pharmacy, Mie University Hospital, Tsu, Japan;11. Department of Breast Surgery, Hokkaido Cancer Center, Sapporo, Japan;12. Department of Surgery, Matsusaka City Hospital, Matsusaka, Japan;13. Division of Hematology/Oncology, Suzuka General Hospital, Suzuka, Japan;14. Department of Surgery, Mie Prefectural General Medical Center, Yokkaichi, Japan;15. Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan;16. Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan;17. Department of Medical Innovation, Osaka University Hospital, Suita, Japan |
| |
| Abstract: | IntroductionBreast cancer patients often receive anthracycline-based chemotherapy, and chemotherapy-induced nausea and vomiting (CINV) remains one of the most uncomfortable and distressing adverse reactions. Poor control of CINV reduces the relative dose intensity of chemotherapy agents, which has been associated with poor clinical outcomes and shorter survival. The aim of the present study was to identify genetic risk factors associated with anthracycline-based CINV.Patients and MethodsWe evaluated CINV attributable to anthracycline-based chemotherapy in Japanese breast cancer patients treated with an antiemetic regimen that included palonosetron, aprepitant, and dexamethasone. Furthermore, we investigated the associations between CINV and single nucleotide polymorphisms in 6 candidate genes.ResultsEmesis episodes were rarely observed in the 125 patients included in the present survey (7.2%; n = 9); however, significant nausea occurred in more than one half of the patients (52.8%; n = 66). In particular, acute significant nausea was not effectively controlled. Multivariate logistic regression analysis revealed that the ABCG2 (rs2231142) AA genotype is significantly associated with acute significant nausea (odds ratio, 4.87; 95% confidence interval, 1.01-23.60; P = .049).ConclusionThe findings of the present study provide significant insights for developing personalized antiemetic strategies for breast cancer patients receiving anthracycline-based chemotherapy. |
| |
| Keywords: | ABCG2 Antiemetic agents Chemotherapy-induced nausea and vomiting Genetic factors Single nucleotide polymorphism |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
